Rasmus Skaarup Mortensen
Dr. Mortensen received his doctorate in immunology and vaccinology at University of Copenhagen and has a key interest in understanding the interplay between bacterial pathogens and the host. His research is focused on protective mechanisms of vaccine mediated immunity with the overall goal of developing novel vaccine concepts. This includes:
- Discovery of novel vaccine targets and rational vaccine design
- Immunological studies of T cell homing and functionality
- Host-directed therapy and therapeutic vaccination
- Optimization of vaccine immunogenicity using new adjuvants and alternative delivery forms
His expertise covers development activities from early discovery to testing and transitioning into clinical trials. Currently, the main focus of his research is to develop an improved next-generation tuberculosis vaccine.
- Scientific project leader and head of the TB Vaccine Research unit
- Transitioning of research projects into product development and clinical testing
- Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM. A Phase I/II randomized trial of H56:IC31 vaccination and adunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. 2021 Nat Comm 22;12(1):6774
- Woodworth JS, Clemmensen HS, Battey H, Dijkman K, Lindenstrøm T, Laureano RS, Taplitz R, Morgan J, Aagaard C, Rosenkrands I, Arlehamn CSL, Andersen P, Mortensen R. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. 2021 Nat Commun 18;12(1):6658
Clemmensen HS, Dube J-Y, McIntosh F, Rosenkrands I, Jungersen G, Aagaard C, Andersen P, Behr MA, Mortensen R. In vivo antigen expression regulates CD4 T cell differentiation and vaccine efficacy against Mycobacterium tuberculosis infection. 2021 mBio. 20;12(2):e00226-21
- Jørgensen MJ, Nore KG, Aass HC, Layre E, Nigou J, Mortensen R, Tasken K, Kvale D, Jenum S, Tonby K, Dyrhol-Riise AM. Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. 2021 Front Cell Infect Microbiol 11:669623
- Clemmensen HS, Knudsen NPH, Billeskov R, Rosenkrands I, Jungersen G, Aagaard C, Andersen P, Mortensen R. Rescuing ESAT-6 specific CD4 T cells from terminal differentiation is critical for long-term control of murine Mtb infection.2020 Front. Immunol. 11:2859.
- Aagaard C, Knudsen NPH, Sohn I, Izzo AA, Kim H, Kristiansen EH, Lindenstrøm T, Agger EM, Rasmussen M, Shin SJ, Rosenkrands I, Andersen P, Mortensen R. Immunization with Mycobacterium tuberculosis–Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette–Guérin Vaccination and Improves Protection in Mice. 2020 J. Immunol. 205(8):2146-55